RRx-001 (nibrozetone)/Wherewolf

Oct 27, 2023

Raise your hand if you think RRx-001 (nibrozetone) should wear a mask.

Not to suggest that a real-life therapeutic agent like RRx-001 (nibrozetone) is in any way like the fictional heroes/vigilantes with alter egos from comic books, clearly it isn’t, but that said Bruce Wayne/Batman, Matt Murdoch/Daredevil, Peter Parker/Spiderman, Barbara Gordon/Batgirl, Don Diego Vega/Zorro etc. all wear one to hide their true faces from evil-doers.

So why not also RRx-001 (nibrozetone) which faces off against perhaps the worst evil-doer of all—disease? More than one disease, in fact.

Outside tumors and in non-diseased tissues RRx-001 (nibrozetone) is a mild-mannered ‘do-gooder’ that patrols to keep the peace and to arrest oxidation and inflammation through inhibition of the NLRP3 inflammasome and activation of the Nrf2 antioxidant transcription factor.

Inside tumors and other diseased tissues, however, RRx-001 (nibrozetone) transforms like a werewolf into a deadlier version of itself, releasing ‘sharp fanged’ metabolites such as nitric oxide. Instead of Werewolf, we refer to the RRx-001 (nibrozetone) alter ego as “Wherewolf.” 🐺

The intentional spelling emphasizes that RRx-001 (nibrozetone) only shape shifts, not when a full moon appears, of course, but “where” disease is present. In other words, where tumors, abscesses, granulomas, stroke, transient ischemic attack, heart failure, MI, neurodegeneration, endometriosis, etc. are found.

This means, we hope, that in the face of diseases of all stripes and variations, RRx-001 (nibrozetone), if administered, is likely to target them.